MedMythBusters: Obesity

CME

This activity is provided by DKBmed and the Institute for Johns Hopkins Nursing (IJHN). This activity is supported by in-kind support from DKBmed and the Institute for Johns Hopkins Nursing (IJHN). 

Enduring internet activity

Estimated time to complete this activity: 15 minutes 

There is no fee for this educational activity. 

Program release: July 31, 2024 

Program expires: July 31, 2025 

For NCPD questions, please contact the IJHN office at [email protected] 

Target Audience

This initiative is designed to reach clinicians who treat patients with obesity. 

Learner Outcomes

After completing this activity, the participant should be better able to: 

  • Describe the efficacy and safety of GLP-1 agonists or GIP/GLP-1 agonists to treat obesity 

Faculty

Maria Isabel Esparza, MD 
Board Certified in Internal Medicine,
Endocrinology and Metabolism and Obesity 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by DKBmed and the Institute for Johns Hopkins Nursing.  

Continuing Nursing Education

The maximum number of hours awarded for this nursing continuing professional development activity is 0.5 contact hours. This 0.5 contact hour NCPD activity is provided by the Institute for Johns Hopkins Nursing. Statements will be awarded for this educational activity until July 31, 2025. 

Accreditation Statement

The Institute for Johns Hopkins Nursing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. 

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity. 

Disclosure of Conflicts of Interest

It is the policy of The Institute for Johns Hopkins Nursing to require our continuing professional development program faculty and planning committee members to disclose all relevant financial relationships with ineligible companies.  The IJHN has established policies to identify and mitigate relevant financial relationships.  

The planning committee and program faculty report that they do not have relevant financial relationships with ineligible companies to disclose. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Non-Endorsement of Products

The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of the IJHN name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients. 

Request for Credit/Fees

There are no fees for participating and receiving NCPD contact hours credit for this activity. During the period of July 31, 2024 through July 31, 2025, participants must read the learning objectives and faculty disclosures and study the educational activity. In order to receive NCPD contact hours, participants must also complete and submit an evaluation. If you wish to receive acknowledgment for completing this activity, please complete the evaluation. 

Hardware/Software Requirements

Include minimum hardware, software, internet connectivity and connection speed requirements for accessing the internet-based activity.